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Aim. To study the molecular mechanisms of reactive oxygen species (ROS)  involvement in circumventing the 
cancer drug resistance by novel angucycline antibiotic landomycin E in HL-60 human leukemia cells and its 
drug-resistant sublines HL-60/adr and HL-60/vinc. Methods. MTT assay, trypan blue exclusion test, DCFDA 
and JC-1 staining of cells. Results. Landomycin E (LE) leads to a massive hydrogen peroxide production in 
HL-60 cell line already 1h after the drug addition to the cell culture, while depolarization of mitochondria is 
observed only at 6-12h, which indicates on the extra-mitochondrial ROS production by LE. The drug-resistant 
cells of HL-60/vinc (P-gp+) despite 100-fold resistance to doxorubicin (Dx) action, demonstrated no difference 
in the resistance to LE compared to the parental cell line, while HL-60/adr line (MRP-1+), which was found to 
be 200-fold resistant to Dx action, had shown a weak (2-fold) decrease in sensitivity to LE. Circumvention of 
drug resistance by LE in HL-60/adr cells was accompanied by a 2-fold higher level of H2O2 compared to the 
wild-type cells, but the mitochondrial respiratory chain inhibitors had no impact on this phenomenon. 
Conclusions. LE-induced cell death is accompanied by massive hydrogen peroxide production, consisting of 
two peaks – major one at 1h and secondary at 12h after drug treatment. The highest ROS production was ob-
served in HL-60/adr cells, which have shown a 2-fold increase of resistance to LE compared to parental cells. 
However, mitochondria seem to play secondary role in this process, due to the fact that use of specific inhibitors 
of mitochondrial respiratory chain did not affect the early ROS burst, induced by LE in tumor cells.
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Introduction
Despite advancement of modern pharmacology in the 
development of efficient anticancer drugs, the overall 
ratio of successful results of the metastatic cancer che-
motherapy still remains rather low. Compared to the 
golden chemotherapy standards (anthracyclines and 
vinca alkaloids), developed in early 1960s, over the 
last decade the specificity of modern targeted medi-
cines became markedly higher and their side effects 
significantly diminished. However, the average sur-
vival time of patients with disseminated cancer did 
not considerably increase] [1].
Such ineffectiveness of cancer chemotherapy is 
explained by the rapid development of acquired 
multi-drug resistance (MDR) of tumor cells to the 
anticancer drugs, which is found in 30-50% of can-
cer patients already in a year after the treatment 
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start [2]. The MDR phenotype is characterized by 
the simultaneous resistance of cancer cells to the 
pharmacologically and structurally diverse drugs [3]. 
It could be a cause of the poor prognosis and lower 
survival rate in several types of cancer such as gas-
tric cancer, breast cancer, ovarian cancer, pancreatic 
cancer, and leukemia [4, 5] 
MDR is related to an increased production of the 
ATP-Binding Cassette (ABC) transport proteins. the 
membrane-bound proteins that extrude a variety of 
anticancer drugs from the tumor cells using ATP hy-
drolysis. Until now, 48 human ABC genes have been 
identified and classified into seven subfamilies based 
on the sequence homology and domain structure [1]. 
In addition to their physiological expression in normal 
tissues, these proteins were found to be over-ex-
pressed in the human tumors, which significantly low-
ers their response to the chemotherapy treatment. 
Although all types of ABC transporters are involved 
in drug resistance, most studies on the ABC transport-
er protein in cancer have focused on three proteins: 
P-gp (p-glycoprotein), MRP-1 (multidrug-resistance 
associated protein), and BCRP (breast cancer resis-
tance protein). Each of the above drug transporters is 
specific to a certain type of substrates. In particular, 
P-glycoprotein is responsible for resistance to colchi-
cine, dexamethasone, doxorubicin, vinblastine, and 
etoposide, whereas the over-expression of MRP-1 
protein results in resistance to vincristine and doxoru-
bicin[6, 7]. In turn, bcrp, besides resistance to metho-
trexate and mitoxantrone, is also responsible for the 
cancer cell resistance to targeted chemotherapies, 
such as imatinib and lapatinib, which makes it espe-
cially important in modern cancer chemotherapy [8].
Thus, the development of novel anticancer drugs, 
capable of circumventing the cancer drug resistance 
in different ways, which could not be inhibited by any 
of known drug resistance mechanisms, remains an 
important task of the current pharmacology and medi-
cine. Here, one of promising approaches is searching 
for natural compounds, the anticancer activities of 
which could not be affected by the ABC-transporter 
proteins. Landomycins are a novel group of angucy-
cline antibiotics possessing a strong antineoplastic 
potential. All natural landomycins identified to date, 
share the same aglycon (landomycinone) group and 
vary only in their oligosaccharide chain, a linear gly-
cosidic chain containing only di- and trideoxysugars 
(β-D-olivose and α-L-rhodinose [9]. They show a 
broad activity against many cancer cell lines, with the 
general tendency that the compounds with longer sac-
charide chains possess a higher antitumor poten-
tial [10, 11]. 
Previously, we studied the cellular and molecular 
mechanisms of antitumor activity of one landomycin 
family member – landomycin E, possessing three 
sugar residues in its saccharide chain. It was shown 
[12, 13] that this drug could overcome the multidrug 
resistance of cancer cells to chemotherapy treatment 
due to the over-expression of ABC-transporters. It 
wasalso shown by us, that the anticancer activity of 
another member of this family – landomycin A – is 
accompanied by massive ROS burst at early time-
points of its action, but the molecular mechanisms of 
this phenomenon still remain unclear [14].
The main aim of the current study was to investi-
gate the ROS profile in HL-60 leukemia cells and the 
drug-resistant HL-60/adr and HL-60/vinc sublines 
under LE treatment in vitro, and to evaluate a possi-
ble role of mitochondria in circumvention of cancer 
drug resistance by LE using specific mitochondrial 
respiratory chain inhibitors. A well-known antican-
cer drug doxorubicin was used for the comparison .
Materials and Methods
Materials
LE-overproducing Streptomyces globisporus 1912 
strain was obtained in the laboratory of Prof. B. 
Matselyukh (D.K. Zabolotny Institute of Micro bio-
logy and Virology, National Academy of Sciences of 
Ukraine, Kyiv). LE (99.5% purity, according to 
HPLC data) was prepared in the laboratory of Prof. 
J. Rohr (University of Kentucky, USA) and dis-
solved in absolute ethanol to obtain a 4 mg/ml stock 
solution. Doxorubicin hydrochloride was obtained 
from Pfizer (New York, NY). Diphenylene Iodonium 
(DPI), antimycin A (AMA), oligomycin A (OM), 
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N-acetylcysteine (NAC) and sodium pyruvate were 
purchased from Sigma-Aldrich (St. Louis, MO).
Cell culture and treatments
Human leukemia cells of HL-60 line, its drug-resistant 
sublines HL-60/adr (MRP-1 overexpression) and HL-
60/vinc (P-glycoprotein overexpression) were ob-
tained from the cell culture collections at Vienna 
Medical University, Institute of Cancer Research, from 
ATCC. Cells were cultured in RPMI medium, supple-
mented with 10% fetal calf serum (Sigma-Aldrich), 50 
µg/ml streptomycin (Sigma-Aldrich), 50 units/ml pen-
icillin (Sigma-Aldrich) in 5% CO2-containing humidi-
fied atmosphere at 37 °C. For experiments[, the] cells 
were seeded into 24-well tissue culture plates (Greiner 
Bio-one, Germany). Short-term (24h) cytotoxic effect 
of antitumor drugs was studied under the Evolution 
300 Trino microscope (Delta Optical, Poland) after 
cell staining with trypan blue dye (0.1%). 
DPI (3 mM stock solution) was dissolved in 
DMSO, while antimycin A and oligomycin A were 
dissolved in absolute ethanol to obtain 2 mM stock 
solutions. NAC (0.5 M) and D-mannitol (10 M) 
were dissolved in 1x phosphate buffered saline 
(PBS). Modulators were added to cell culture 30 min 
before addition of anticancer drugs, and final con-
centration of NAC was 1 mM, sodium pyruvate 
10 mM, DPI and Oligomycin A – 4 µM. Stock solu-
tions of aforementioned reagents were dissolved in 
PBS before addition to cell culture.
For long-term (72h) cytotoxicity assays Jurkat 
cells were plated (5x103) in 100 µl per well in 96-
well plates, and allowed to grow for 24 h. Drugs 
were added in another 100 µl culture medium (final 
concentration of DPI – 0.5 µM, oligomycin A – 
1 µM, antimycin A – 2 µM, sodium pyruvate – 
10 mM, NAC – 1 mM) and cells were exposed for 
72 h. The proportion of viable cells was determined 
by EZ4U assay according to the manufacturer’s rec-
ommendations (EZ4U, Biomedica, Vienna, Austria). 
Cytotoxicity was expressed as IC50 values calculated 
from full dose-response curves (drug concentration 
including 50% reduction in cell survival comparing 
to the control cultured in parallel without drug). 
Flow cytometric assays
Analyses were performed using a FACScalibur ﬂow 
cytometer (BD Biosciences, San Jose, CA) and 
Summit v3.1 software (Cytomation, Inc., Fort Collins, 
CO). HL-60, HL-60/adr and HL-60/vinc leukemia 
cells were treated as indicated in the figures. 
Cellular ROS contents were measured by incubat-
ing the control or drug-treated cells with ﬂuorescent 
dye dihydrodichloroﬂuoresceindiacetate (H2DCFDA, 
H2O2-specific) in concentration 10 μM of H2DCFDA 
at 37 °C for 30 min. After incubation with the 
ﬂuorochrome, cells were washed with PBS and im-
mediately analyzed at FL1 channel of FACSCalibur 
ﬂow cytometer (BD Biosciences, San Jose, CA)
Breakdown of ΔΨm mitochondrial membrane po-
tential was determined by FACS analysis using JC-1 
(5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimid-
azolylcarbocyanine iodide). For this purpose the 
Mitochondrial Membrane Potential Detection Kit 
(Stratagene, La Jolla, CA, USA) was used, as de-
scribed in the manufacturer’s instruction. 106 HL-60 
or HL-60/adr cells were treated for 1, 3, 6, 12 and 
24 h with the tested drugs. After PBS washing, cells 
were incubated for 10 min in freshly prepared JC-1 
solution (10 mg/ml in culture medium) at 37 °C. 
Spare dye was removed by PBS washing and cell-
associated ﬂuorescence was measured with FACS.
Statistical analysis
If not stated otherwise, data are expressed as mean 
± SD. The results were analyzed using GraphPad 
Prism software. Statistical analyses were performed 
using t-test or two-way analysis of variance 
(ANOVA). To examine differences between the drug 
treatment responses, Bonferroni post-tests were con-
ducted. P values below 0.05 were considered as sta-
tistically significant and marked with stars: * p<0.05; 
** p<0.01; *** p<0.001.
Results and Discussion
At the first stage of our study, the sensitivity of HL-
60 leukemia cells and their drug-resistant sublines to 
the action of landomycin E (LE) and well-known 
anticancer drug doxorubicin (Dx) was studied in de-
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tail (Fig.1). It was revealed that overexpression of 
P-glycoprotein in HL-60/vinc cells increased their 
resistance profile to Dx 100-fold, while HL-60/adr 
cell line, overexpressing MRP-1, was found to be 
200-fold more resistant to the Dx action compared to 
parental HL-60/wt line (Fig. 1). On [the] contrary, 
no difference in sensitivity of HL-60/wt, HL-60/adr 
and HL-60/vinc cells to [the] LE action was ob-
served at 72h drug incubation time, according to 
MTT tests (Fig.1). 
Short-time drug toxicity experiments (24h incu-
bation), analyzed by trypan blue exclusion test, have 
revealed similar tendencies – 20-fold resistance in-
crease of HL-60/vinc cell line, and 40-fold resistance 
increase of Hl-60/adr cell line towards Dx (Fig.1), 
while for LE the only cells which showed a weak 
(~2-fold) decrease in sensitivity to this drug, were of 
HL-60/adr subline. Thus, the cytotoxic activity of 
LE is almost unaffected by ABC transporters, which 
makes it a promising compound for treatment of 
drug-resistant leukemia.
Previously we demonstrated that one of the lando-
mycin family members – LA, possessing 6 sugar 
residues instead of 3 residues in LE, and thus higher 
Fig. 1. Comparison of anticancer activities of LE and Dx towards human leukemia cells of HL-60 line and its drug-resistant sublines 
HL-60/adr (MRP-1+) and HL-60/vinc (P-gp+). Cell viability was analyzed by MTT assay after 72 h exposure to indicated 
concentrations of LE and Dx, or by trypan blue exclusion assay after 24 h exposure to aforementioned drugs. Graphs represent the 
mean +/- SD of three independent experiments done in triplicates
** p<0.01, *** p<0.001 relative to HL-60/wt cell line, 2-way ANOVA, Bonferroni post-test.
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cytotoxic activity, leads to specific two-phase ROS 
burst in Jurkat T-leukemia cells (Lehka et al, 2015), 
which consists of two peaks 1h and 12h after the tar-
get cell treatment with LA. Mitochondria, being the 
main energetic stations in the eukaryotic cells, are 
also considered to be the main source of ROS [15]. 
Thus, for the identification of nature and source of 
LE-induced ROS, the joint treatment of HL-60/adr/
vinc cells with LE and various ROS scavengers 
(N-acetylcysteine, sodium pyruvate) and mitochon-
drial respiratory chain inhibitors (antimycin A, oli-
gomycin A, DPI) was addressed.
For studying potential impact of mitochondria on 
the cytotoxic activity of LE in vitro several specific 
inhibitors of mitochondrial respiratory chain were 
used, namely DPI (NADPH dehydrogenase inhibitor 
[16]), antimycin A (complex III inhibitor [17]) and 
oligomycin A (ATP-synthetase inhibitor [18]). 
However, it was revealed that all these compounds, 
except antimycin A (2 µM), are toxic to HL-60 leu-
kemia cells, even in very low concentrations (1 µM 
for oligomycin A and 0.5 µM for DPI) (Fig. 2). The 
same tendency was observed also for HL-60/adr 
cells, while HL-60/vinc cell line demonstrated a 
high internal resistance to the action of all tested mi-
tochondrial inhibitors, thus indicating an insignifi-
cant role of mitochondria in the regulation of their 
proliferation and apoptosis. We did not observe any 
statistically significant impact of aforementioned 
compounds on inhibition or stimulation of LE cyto-
toxic action, mainly due to a high toxicity of oligo-
mycin A and DPI towards the tested cell lines at 72h 
incubation. However, in HL-60/vinc cell line, where 
no toxic activity of antimycin A, oligomycin A and 
DPI was observed, they possessed a little, still statis-
tically insignificant impact on lowering antineoplas-
tic action of LE. Thus, mitochondria seem to play 
rather secondary role in the LE-induced cell death. 
For better understanding a role of specific ROS in 
LE-involved cell death, specific hydrogen peroxide 
scavenger sodium pyruvate [19] and wide-scale 
ROS scavenger N-acetylcysteine [20] were ad-
dressed. It was revealed that sodium pyruvate pos-
sessed the moderate cytoprotective activity towards 
the LE action (P<0.05 for HL-60 cells and P<0.01 
for HL-60/adr cells), whereas NAC almost com-
pletely blocked its activity towards all tested cell 
lines (P<0.001). Such unexpectedly high efficiency 
of the NAC action may be explained not only by its 
ROS scavenging activity, but also by its indirect im-
pact on the glutathione level in the cells [20].
Due to the fact that ROS are short-living mole-
cules, MTT assays for 72h drug incubation and try-
pan blue tests for 24h drug treatment may not show 
all the dynamics of cellular processes, taking place 
immediately after drug entry into the cells. For better 
understanding a role of specific ROS and mitochon-
dria at early timepoints of LE action, a level of hy-
drogen peroxide in the cells was measured by ﬂow 
cytometry using DCFDA dye at 1,3,6,12,24h after 
LE addition to studied cell lines. As seen in Fig. 3-5, 
LE leads to the] appearance of typical two-peak 
H2O2 burst in wild-type HL-60 cells, like previously 
observed by us in LA in Jurkat T-cells (Lehka et al, 
2015). At the beginning (1h) the ROS level increases 
3-fold (for 2 µM dose of LE) or 5.5-fold (for 4 µM 
LE), and this process is partially inhibited by 
N-acetylcysteine (see Fig. 3) 
Then at 3h the ROS level under LE treatment rap-
idly drops, almost reaching a control level at 6h, and 
then slowly recovers at 12h, slightly decreasing 
again at 24h (Fig. 3). Mitochondrial respiratory 
chain inhibitors DPI and oligomycin A have no sta-
tistically significant impact on the LE-derived ROS 
production, as seen in Fig. 3, thus confirming our 
previous MTT data (see Fig.2).
However, in the HL-60/adr cell line, which was 
found 2-fold more resistant to the LE action, the 
drug leads to a massive ROS production, which is 
approximately 2-fold higher compared to HL-60/wt 
cells (Fig. 4), and NAC strongly reduces it almost to 
a control level. Surprisingly, the ROS level under LE 
treatment in HL-60/adr cells does not drop as rapidly 
as observed in parental HL-60 line (Fig.4). Instead, 
it slowly decreases from 1h till 24h, so no a “para-
dox” double peak is observed here. Despite major 
H2O2 production, neither DPI, nor oligomycin 
A have significant impact on the ROS production 
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Fig. 2. Study of modulating effect of mitochondrial respiratory chain inhibitors on cytotoxic activities of LE towards human leuke-
mia cells of HL-60 line and its drug-resistant sublines HL-60/adr (MRP-1+) and HL-60/vinc (P-gp+). Cell viability was analyzed by 
MTT assay after 72 h exposure to indicated concentrations of LE. Graphs represent the mean +/- SD of three independent experiments 
done in triplicates
* p<0.05, ** p<0.01, *** p<0.001 relative to LE, 2-way ANOVA, Bonferroni post-test.
DPI – diphenylene iodonium, NAC – N-acetylcyteine, Pyruvate – sodium pyruvate
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Fig. 3. LE leads to significant increase of hydrogen peroxide 
level in human leukemia cells of HL-60 line already at 1h after 
addition to cell culture, which is partially inhibited by N-acetyl-
systeine, but not by mitochondrial respiratory chain inhibitors 
DPI and oligomycin A. The cells were pre-treated for 30 min 
with NAC, DPI and OM then treated with either vehicle, LE 
(2 µM and 4 µM) and then stained with DCFDA for analysis by 
ﬂow cytometry. Bar graphs show an increase (over vehicle con-
trol) in the percentage of cells with positive DCF ﬂuorescence in 
each sample. Baseline level of hydrogen peroxide in control 
cells is taken as 100%.
DPI – diphenylene iodonium, NAC – N-acetylcyteine, OM – 
oligomycin A
* p<0.05, ** p<0.01 relative to control, unpaired t-test.
p<0.05, relative to LE, unpaired t-test.
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Fig. 4. LE leads to over 2-fold increase of hydrogen peroxide 
level in human leukemia cells of HL-60/adr line, overexpressing 
MRP-1, in comparison to HL-60 parental line already at 1h after 
addition to cell culture, which is strongly inhibited by N-acetyl-
systeine, but not by mitochondrial respiratory chain inhibitors 
DPI and oligomycin A. Cells were pre-treated for 30 min with 
NAC, DPI and OM, then treated with either vehicle, LE (2 µM 
and 4 µM) and then stained with DCFDA for analysis by ﬂow 
cytometry. Bar graphs show an increase (over a vehicle control) 
in the percentage of cells with positive DCF ﬂuorescence in each 
sample. A baseline level of hydrogen peroxide in control cells is 
taken as 100%.
DPI – diphenylene iodonium, NAC – N-acetylcyteine, OM – 
oligomycin A
* p<0.05, ** p<0.01 relative to control, unpaired t-test.
p<0.05, relative to LE, unpaired t-test.
198
R. R. Panchuk, L. V. Lehka, J. Rohr et al.
Fig. 5. No major differences in ROS production under LE action 
between P-gp overexpressing HL-60/vinc cell line and HL-60 
parental cells are observed. NADPH oxidase inhibitor DPI par-
tially decreases LE-driven ROS at 24h cells incubation with the 
drug. Cells were pre-treated for 30 min with NAC, DPI and OM, 
then treated with either vehicle, LE (2 µM and 4 µM) and then 
stained with DCFDA for analysis by ﬂow cytometry. Bar graphs 
show an increase (over vehicle control) in the percentage of cells 
with positive DCF ﬂuorescence in each sample. Baseline level 
of hydrogen peroxide in control cells is taken as 100%.
DPI – diphenylene iodonium, NAC – N-acetylcyteine, OM – 
oligomycin A
* p<0.05, ** p<0.01 relative to control, unpaired t-test.
p<0.05, relative to LE, unpaired t-test.
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under the LE action, thus indicatin their weak in-
volvement in this process (Fig. 4).
The only slight ROS-inhibitive effect of DPI to-
wards the LE action was observed in the HL-60/vinc 
cell line, characterized by P-gp overexpression 
(Fig. 5). However, it was much lower compared to 
NAC alone and statistically insignificant. Thus, all 
studied mitochondrial respiratory chain inhibitors 
have a slight effect on the LE-induced ROS produc-
tion, which may indicate the fact that LE leads to the 
extra mitochondrial ROS production. 
For checking this hypothesis, the status of mito-
chondrial membrane in HL-60/wt and HL-60/adr 
cells was tested using JC-1 staining. Unfortunately, 
JC-1, being a mitochondrial stain, was also found by 
us to be a perfect substrate for P-glycoprotein, thus 
the measurement of JC-1 ﬂuorescence in HL-60/
vinc cells was technically impossible due to a mas-
Fig.6. LE leads to late depolarization of mitochondrial membrane in HL-60 and HL-60/adr cells, which takes place 
mainly at 12h after incubation with the drug. DPI possesses strong synergistic effect with LE on depolarization of mi-
tochondria, but this effect is also observed much later (6h) than massive ROS burst at 1h under LE treatment. Cells were 
pre-treated for 30 min with NAC, Oligomycin A or DPI, then treated with either vehicle, LE (2 µM and 4 µM) and then 
stained with JC-1. Intracellular JC-1 ﬂuorescence was measured by FACS and analyzed by Cytomation Summit 
software.
A
C
B
D
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sive dye extrusion from the cells. As seen in Fig. 6, 
LE leads to the late depolarization of mitochondria 
in HL-60 and HL-60/adr cells, reaching its maxi-
mum at 12h timepoint – time, which coincides with 
the second ROS burst observed under the LE action 
(see Fig.3). However, no signs of mitochondria de-
polarization were observed at 1h timepoint in both 
cell lines, where the major ROS peak was observed 
by us (Fig. 3-5). This fact further indicates a second-
ary role of mitochondria in the LE-induced ROS 
production, and corresponds to the second ROS 
burst, but not the first one (1h). At a combination of 
LE and mitochondrial respiratory chain inhibitors it 
was revealed that ATP-synthase inhibitor oligomy-
cin A had no statistically significant impact on the 
LE-induced mitochondrial membrane depolarization 
at 1h, 3h and 6h timepoints, whereas DPI strongly 
enhanced the LE-induced mitochondrial membrane 
depolarization, increasing it 2.5-5-fold depending on 
drug concentration and incubation time (Fig. 6). It is 
known that DPI, blocking mitochondrial Complex I, 
can lead to subsequent oxidative stress in the cells 
[16]. The synergistic action of DPI and LE at 6h 
timepoint on depolarization of mitochondria (Fig. 6) 
clearly indicates that both compounds induce the 
mitochondrial-mediated ROS production. It takes 
place much later (12h) compared to a massive ROS 
burst, caused by LE in both sensitive, and even high-
er, –in doxorubicin-resistant HL-60 cells at 1h. As 
DPI was shown to be a broad NAPDH oxidase in-
hibitor, blocking activity not only of Complex I, but 
also of other membrane-bound NADPH-oxidases 
[16], the LE-induced an early ROS burst cannot be 
explained by involvement of either mitochondria or 
of the plasma membrane ROS-producing enzymes. 
The only possible explanation of this early ROS 
burst is the hydrogen peroxide production by drug 
itself during its entry into the target cell. It has been 
already shown that all compounds containing qui-
none motif in their structure, may be the source of 
ROS itself as the catalyzers of the continuous redox 
cycles [21]. These ROS may be inhibited by cellular 
antioxidant systems, and glutathione system is con-
sidered to be one of the most efficient [22]. 
The GSH level in HL-60/adr cells was shown to be 
2-fold lower in comparison to HL-60/wt cells [23]. This 
may explain the nature of a 2-fold higher ROS burst, 
induced by LE in HL-60/adr cells, as this antioxidant at 
a lower level inside the cells is unable to quickly scav-
enge all hydrogen peroxide, produced by LE. 
Several studies have already demonstrated a tight 
connection between MRP-1 pump and intracellular 
GSH pool, which plays an important role in the func-
tioning of this drug transporter [24]. In particular, 
GSH depletion by buthionine sulphoximine (BSO) 
increases the accumulation of DNR and Rhodamine 
123 (Rh123) in several MRP1-positive cell lines [25], 
thus partially reverting their resistance to these drugs.
The observed connection between the glutathione 
antioxidant system and the MRP-1 expression in 
HL-60/adr cells may explain their higher resistance 
profile to LE. HL-60/vinc cells, which have the basal 
GSH level, do not demonstrate any significant resis-
tance to the LE action, even despite P-gp overex-
pression. Thus, joint targeting of tumor cells by LE 
together with GSH-depleting compounds (such as 
BSO) may be a promising approach in the treatment 
of drug-resistant tumors.
Conclusions
LE effectively circumvents drug resistance of HL-60 
leukemia cells in vitro, caused by P-gp overexpres-
sion, whereas in HL-60/adr cells, characterized by 
MRP-1 overexpression, the activity of this drug drops 
2-fold compared to the parental cell line. The LE-
induced cell death is accompanied by a massive ROS 
burst, consisting of two peaks of hydrogen peroxide 
production – major one at 1h and secondary at 12h 
after drug treatment. The highest ROS production was 
observed in HL-60/adr cells, which have shown 2-fold 
increase of resistance to LE compared to the parental 
cells. However, mitochondria seem to be involved 
only at tetherminal stages of LE-induced apoptosis 
(12h), indicating the extra-mitochondrial ROS produc-
tion by LE at early timepoints. The mitochondrial re-
spiratory chain inhibitors failed to inhibit the LE-
induced ROS burst at both early and terminal stages of 
the LE-induced cell death, and only one of them (DPI) 
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was shown to have synergistic effect with LE on the 
mitochondrial membrane depolarization at 6h of cell 
incubation with the drug. All these data indicate that 
there was no involvement of mitochondria at early 
stages of the LE action, which are accompanied by 
ROS burst, possibly produced by the drug itself due to 
its specific chemical structure. A low glutathione level 
in HL-60/adr cells, which is a well-known antioxidant, 
may explain a 2-fold higher ROS burst, observed un-
der the cytotoxic action of LE towards these cells.
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Мітохондрії не відіграють основної ролі в індукції 
оксидативного стресу при доланні множинної 
лікарської стійкості в лейкозних клітинах лінії HL-60 
ландоміцином Е
Р. Р. Панчук, Л. В. Легка, Ю. Рор, В. Бергер, Р. С. Стойка
Мета. Молекулярні механізми участі активних форм кисню 
(АФК) в доланні множинної лікарської стійкості злоякісних 
клітин новим ангуцикліновим антибіотиком ландоміцином E в 
лейкозних клітинах людини лінії HL-60 і її сублініях HL-60/adr 
і HL-60/vinc, резистетних до хіміотерапії. Методи. МТТ тест, 
тест на життєздатність клітин з трипановим синім, фарбування 
клітин флуоресцентними барвниками DCFDA і JC-1. 
Результати. Ландоміцин Е (ЛЕ) призводить до значного зрос-
тання продукції пероксиду водню в клітинах лінії HL-60 вже 
на 1 год після додавання препарату до культури клітин, в той 
час як деполяризация мітохондрій спостерігаються тільки на 
6-12 год, що вказує на позамітохондріальне джерело АФК за дії 
цього антибіотика. Клітини лінії HL-60/vinc (P-глікопротеїн +), 
незважаючи на 100-кратне зростання стійкості до доксорубі-
цину (Dx), продемонстрували ідентичну чутливість до ЛЕ в 
порівнянні з вихідною клітинною лінією, в той час як клітини 
лінії HL-60/adr (MRP- 1+), які проявляли 200-кратне зростання 
стійкості до дії Dx, показали слабке (в 2 рази) зниження чутли-
вості до ЛЕ. Долання стійкості до ліків ландоміцином Е у клі-
тинах лінії HL-60/adr супроводжувалося 2-кратним зростан-
ням рівня Н2О2 в порівнянні з клітинами дикого типу, але міто-
хондріальні інгібітори дихального ланцюга не проявляли нія-
кого впливу на це явище. Висновки. ЛЕ-індукована загибель 
пухлинних клітин супроводжується масовим виробництвом 
перекису водню, що складається з двох піків – основного (1 
год) і вторинного (на 12 год дії препарату). Найвища продукція 
АФК спостерігалася в клітинах лінії HL-60/adr, які показали 
2-кратне збільшення стійкості до ЛЕ в порівнянні з вихідною 
лінією HL-60. Мітохондрії, очевидно, відіграють вторинну 
роль в цьому процесі, оскільки використання специфічних ін-
гібіторів дихального ланцюга мітохондрій ніяк не вплинуло на 
ранню індукцію АФК за дії ЛЕ в пухлинних клітинах.
К л юч ов і  с л ов а: ландоміцин Е, ROS, мітохондрії, стій-
кість пухлин до ліків, апоптоз
Митохондрии не играют основной роли в индукции 
оксидативного стресса при преодолении множественной 
лекарственной устойчивости в лейкозных клетках 
линии HL-60 ландомицином Е
Р. Р. Панчук, Л. В. Легкая, Ю. Рор, В. Бергер, Р. С. Стойка
Цель. Молекулярные механизмы участия активных форм кис-
лорода (АФК) в преодолении множественной лекарственной 
устойчивости злокачественных клеток новым ангуциклино-
вым антибиотиком ландомицином E в лейкозных клетках че-
ловека линии HL-60 и ее сублиниях HL-60/adr и HL-60/vinc, 
резистентных к химиотерапии. Методы. МТТ тест, тест на 
жизнеспособность клеток с трипановым синим, окраска кле-
ток флуоресцентными красителями DCFDA и JC-1. 
Результаты. Ландомицин Е (ЛЕ) приводит к значительному 
росту продукции пероксида водорода в клетках линии HL-60 
уже на 1 ч после добавления препарата к культуре клеток, в то 
время как деполяризация митохондрий наблюдаются только на 
6-12 ч, что указывает на внемитохондриальный источник АФК 
происхождения при действии этого антибиотика. Клетки ли-
нии HL-60 vinc (P-гликопротеин+), несмотря на 100-кратный 
рост устойчивости к доксорубицину (Dx), продемонстрирова-
ли идентичную чувствительность к ЛЕ по сравнению с исход-
ной клеточной линией, в то время как клетки линии HL-60/adr 
(MRP-1+), которые проявляли 200-кратный рост устойчивости 
к действию Dx, показали слабое (в 2 раза) снижение чувстви-
тельности к ЛЕ. Преодоление устойчивости к лекарствам лан-
домицином Е в клетках линии HL-60/adr сопровождалось 
2-кратным ростом уровня Н2О2 по сравнению с клетками дико-
го типа, но митохондриальные ингибиторы дыхательной цепи 
не проявляли никакого влияния на это явление. Выводы. ЛЕ-
индуцированная гибель опухолевых клеток сопровождается 
массовым производством перекиси водорода, состоящей из 
двух пиков – основного (1 час) и вторичного (на 12 ч действия 
препарата). Самая высокая продукция АФК наблюдалась в 
клетках линии HL-60/adr, которые показали 2-кратное увели-
чение устойчивости к ЛЕ по сравнению с исходной линией 
HL-60. Митохондрии, очевидно, играют вторичную роль в 
этом процессе, поскольку использование специфических ин-
гибиторов митохондриальной дыхательной цепи никак не по-
влияло на раннюю индукцию АФК при действии ЛЕ на опухо-
левые клетки.
К л юч е в ы е  с л ов а: ландомицин Е, ROS, митохондрии, 
устойчивость опухолей к лекарствам, апоптоз
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